Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Linezolid Resistance in Staphylococcus haemolyticus - Case Series and Review of Literature

Author(s): Varsha Gupta, Neelam Gulati, Shiwani Sharma*, Ravi Gupta, Ashwani Soni and Jagdish Chander

Volume 20, Issue 5, 2020

Page: [713 - 717] Pages: 5

DOI: 10.2174/1871526519666190807152850

Price: $65

Abstract

Background: Coagulase negative Staphylococci (CoNS) are important. The common antibiotics used for the treatment of the infections caused by CoNS are penicillin, oxacillin, ciprofloxacin, clindamycin, erythromycin, gentamicin, and vancomycin. Linezolid is an oxazolidinone group of antibiotic with activity against Gram-positive bacteria. It is used for the treatment of serious infections caused by Gram-positive bacteria resistant to other antibiotics, including streptococci, vancomycin-resistant enterococci (VRE).

Aims and Objective: This study emphasizes on the judicious use of newer antibiotics to contain the spread of resistance.

Method: We are discussing five cases of Linezolid resistant Staphylococcus Haemolyticus which were reported in our laboratory during one year from patients with device related infections and also review of literature is being presented for an update.

Result: In our study, the isolates were resistant to other groups of antimicrobials but susceptible to glycopeptides. All the isolates were methicillin-resistant.

Conclusion: Linezolid is approved as an alternative drug to be given for catheter-related bloodstream infections. In earlier studies, linezolid-resistant staphylococci have been reported increasingly all over the world. This study is to create awareness amongst clinicians that improper and excessive use of linezolid will make this antibiotic-resistant and thus will be of no help in future, so judicious and relevant use of antibiotics needs to be emphasized.

Keywords: Coagulase negative Staphylococci, antibiotics, drug resistance, vancomycin-resistant enterococci, linezolid, Staphylococcus haemolyticus.

[1]
"19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO., 2015 April; Retrieved May 10 2015.
[2]
Meka, V.G.; Gold, H.S. Antimicrobial resistance to linezolid. Clin. Infect. Dis., 2004, 39(7), 1010-1015.
[http://dx.doi.org/10.1086/423841] [PMID: 15472854]
[3]
Mermel, L.A.; Allon, M.; Bouza, E.; Craven, D.E.; Flynn, P.; O’Grady, N.P.; Raad, I.I.; Rijnders, B.J.; Sherertz, R.J.; Warren, D.K. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin. Infect. Dis., 2009, 49(1), 1-45.
[http://dx.doi.org/10.1086/599376] [PMID: 19489710]
[4]
Flanagan, S.D.; Bien, P.A.; Muñoz, K.A.; Minassian, S.L.; Prokocimer, P.G. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy, 2014, 34(3), 240-250.
[http://dx.doi.org/10.1002/phar.1337] [PMID: 23926058]
[5]
Decousser, J.W.; Desroches, M.; Bourgeois-Nicolaos, N.; Potier, J.; Jehl, F.; Lina, G.; Cattoir, V.; Vandenesh, F.; Doucet-Populaire, F. Susceptibility trends including emergence of linezolid resistance among coagulase-negative staphylococci and meticillin-resistant Staphylococcus aureus from invasive infections. Int. J. Antimicrob. Agents, 2015, 46(6), 622-630.
[http://dx.doi.org/10.1016/j.ijantimicag.2015.07.022] [PMID: 26453147]
[6]
Becker, K.; Heilmann, C.; Peters, G. Coagulase-negative staphylococci. Clin. Microbiol. Rev., 2014, 27(4), 870-926.
[http://dx.doi.org/10.1128/CMR.00109-13] [PMID: 25278577]
[7]
Lee, C.R.; Lee, J.H.; Park, K.S.; Jeong, B.C.; Lee, S.H. Quantitative proteomic view associated with resistance to clinically important antibiotics in Gram-positive bacteria: a systematic review. Front. Microbiol., 2015, 6, 828.
[http://dx.doi.org/10.3389/fmicb.2015.00828] [PMID: 26322035]
[8]
Bannerman, T.L. Staphylococcus, Micrococcus, and other catalasepositive cocci that grow aerobically.Manual of clinical microbiology, 8th ed; Murray, P.R.; Baron, E.J.; Jorgensen, J.H.; Pfaller, M.A.; Yolken, R.H., Eds.; American Society for Microbiology: Washington, D.C , 2003.
[9]
Hugonnet, S.; Sax, H.; Eggimann, P.; Chevrolet, J-C.; Pittet, D. Nosocomial bloodstream infection and clinical sepsis. Emerg. Infect. Dis., 2004, 10(1), 76-81.
[http://dx.doi.org/10.3201/eid1001.030407] [PMID: 15078600]
[10]
Mazzariol, A.; Lo Cascio, G.; Kocsis, E.; Maccacaro, L.; Fontana, R.; Cornaglia, G. Outbreak of linezolid-resistant Staphylococcus haemolyticus in an Italian intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis., 2012, 31(4), 523-527.
[http://dx.doi.org/10.1007/s10096-011-1343-6] [PMID: 21792559]
[11]
Rodríguez-Aranda, A.; Daskalaki, M.; Villar, J.; Sanz, F.; Otero, J.R.; Chaves, F. Nosocomial spread of linezolid-resistant Staphylococcus haemolyticus infections in an intensive care unit. Diagn. Microbiol. Infect. Dis., 2009, 63(4), 398-402.
[http://dx.doi.org/10.1016/j.diagmicrobio.2008.12.008] [PMID: 19232856]
[12]
Cai, J.C.; Hu, Y.Y.; Zhang, R.; Zhou, H.W.; Chen, G.X. Linezolid-resistant clinical isolates of meticillin-resistant coagulase-negative staphylococci and Enterococcus faecium from China. J. Med. Microbiol., 2012, 61(Pt 11), 1568-1573.
[http://dx.doi.org/10.1099/jmm.0.043729-0] [PMID: 22899781]
[13]
Matlani, M.; Shende, T.; Bhandari, V.; Dawar, R.; Sardana, R.; Gaind, R. Linezolid-resistant mucoid Staphylococcus haemolyticus from a tertiary-care centre in Delhi. New Microbes New Infect., 2016, 11, 57-58.
[http://dx.doi.org/10.1016/j.nmni.2016.02.010] [PMID: 27274851]
[14]
Cui, L.; Wang, Y.; Li, Y.; He, T.; Schwarz, S.; Ding, Y.; Shen, J.; Lv, Y. Cfr-mediated linezolid-resistance among methicillin-resistant coagulase-negative staphylococci from infections of humans. PLoS One, 2013, 8(2)e57096
[http://dx.doi.org/10.1371/journal.pone.0057096] [PMID: 23437319]
[15]
Rajan, V.; Kumar, V.G.; Gopal, S. A cfr-positive clinical staphylococcal isolate from India with multiple mechanisms of linezolid-resistance. Indian J. Med. Res., 2014, 139(3), 463-467.
[PMID: 24820843]
[16]
Gupta, V.; Garg, S.; Jain, R.; Garg, S.; Chander, J. Linezolid resistant Staphylococcus haemolyticus: first case report from India. Asian Pac. J. Trop. Med., 2012, 5(10), 837-838.
[http://dx.doi.org/10.1016/S1995-7645(12)60155-2] [PMID: 23043928]
[17]
Fajardo Olivares, M.; Hidalgo Orozco, R.; Rodríguez Garrido, S.; Rodríguez-Vidigal, F.F.; Vera Tomé, A.; Robles Marcos, M. Activity of vancomycin, ciprofloxacin, daptomycin, and linezolid against coagulase-negative staphylococci bacteremia. Rev. Esp. Quimioter., 2011, 24(2), 74-78.
[PMID: 21666998]
[18]
Czekaj, T.; Ciszewski, M.; Szewczyk, E.M. Staphylococcus haemolyticus - an emerging threat in the twilight of the antibiotics age. Microbiology, 2015, 161(11), 2061-2068.
[http://dx.doi.org/10.1099/mic.0.000178] [PMID: 26363644]
[19]
Biavasco, F.; Vignaroli, C.; Varaldo, P.E. Glycopeptide resistance in coagulase-negative staphylococci. Eur. J. Clin. Microbiol. Infect. Dis., 2000, 19(6), 403-417.
[http://dx.doi.org/10.1007/s100960000299] [PMID: 10947214]
[20]
Pillai, S.K.; Sakoulas, G.; Wennersten, C.; Eliopoulos, G.M.; Moellering, R.C., Jr; Ferraro, M.J.; Gold, H.S. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J. Infect. Dis., 2002, 186(11), 1603-1607.
[http://dx.doi.org/10.1086/345368] [PMID: 12447736]
[21]
Morales, G.; Picazo, J.J.; Baos, E.; Candel, F.J.; Arribi, A.; Peláez, B.; Andrade, R.; de la Torre, M.A.; Fereres, J.; Sánchez-García, M. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. Dis., 2010, 50(6), 821-825.
[http://dx.doi.org/10.1086/650574] [PMID: 20144045]
[22]
Flamm, R.K.; Mendes, R.E.; Hogan, P.A.; Streit, J.M.; Ross, J.E.; Jones, R.N. Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014). Antimicrob. Agents Chemother., 2016, 60(4), 2273-2280.
[http://dx.doi.org/10.1128/AAC.02803-15] [PMID: 26833165]

Rights & Permissions Print Cite
Article Metrics
18
© 2024 Bentham Science Publishers | Privacy Policy